Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026

Contributed by: PR Newswire

Tags

H-Lundbeck-AS

More Like This

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Exidavnemab phase 2a study expanded to include MSA patients

Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026

Business Wire logo

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026